<DOC>
	<DOCNO>NCT01327573</DOCNO>
	<brief_summary>This study design assess effectiveness eculizumab recipient kidney transplantation donor-specific antibody ( DSA ) worsen kidney function ass eculizumab improve endothelial cell injury kidney . The investigator hypothesize complement inhibition eculizumab reduce allograft injury , result less complement-mediated injury endothelial cell less endothelial cell activation .</brief_summary>
	<brief_title>Eculizumab Therapy Chronic Complement-Mediated Injury Kidney Transplantation</brief_title>
	<detailed_description>This study address clinical challenge currently exist management kidney transplant recipient develop de novo DSA , deteriorate graft function , yet establish treatment alternative . This randomized , open-label , pilot intervention trial . Post transplant patient deteriorate renal function ( defined 20 % reduction GFR ) screen development DSA biopsied presence C4d deposition . All patient DSA meeting inclusion/exclusion criterion undergo protocol renal biopsy assess C4d deposition . Participants randomize treatment eculizumab plus standard care ( SOC ) SOC . Randomization stratify C4d status ( C4d+/C4d- ) 10 subject ( 7 eculizumab , 3 SOC ) stratum . Eculizumab antibody develop inhibit complement protein C5 . Eculizumab deliver via IV accord follow schedule : - Eculizumab Induction 600mg IV every 7 day 4 dos - Eculizumab 900mg IV 7 day later - Eculizumab Maintenance 900mg IV every 14 day total 26 week</detailed_description>
	<mesh_term>Complement System Proteins</mesh_term>
	<criteria>Kidney transplant recipient great 6 month date transplant Must standard immunosuppression : tacrolimus , mycophenolate mofetil , prednisone stable tacrolimus trough level past 3 month Deteriorating renal function , define 20 % reduction GFR ( MDRD calculation ) Presence DSA , define MFI &gt; 1100 Renal biopsy demonstrating diffuse , irreversible endstage organ injury ( i.e . stage IV Fibrosis ) Renal biopsy demonstrate C4d deposition ( stratum 1 ) C4d deposition ( stratum 2 ) History CMV , BK , HSV viral infection History chronic , recurrent bacterial infection Evidence tubulitis renal biopsy morphological feature acute cellular rejection acute humoral rejection Renal biopsy demonstrating diffuse , irreversible endstage organ injury Absolute GFR &lt; 25 ( MDRD calculation ) Inability provide informed consent History poor vascular access Refusal use double barrier contraception study participation Patients actively enrol clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>chronic kidney allograft injury</keyword>
	<keyword>complement protein</keyword>
	<keyword>eculizumab</keyword>
	<keyword>Kidney transplantation</keyword>
</DOC>